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late reperfusion injury but have never before been
directly compared in a single standardized model. Some
of the more promising interventions include pentoxi-
fylline, inositol polyanions (typified by inositol hexak-
isphosphate [InSP6]), and the potent nitric oxide donor,
SIN-1 (3-morpholinosydnonimine).
Pentoxifylline administration has been successful in
ameliorating reperfusion injury after skeletal muscle
ischemia and experimental lung and liver transplanta-
tion. It acts through a variety of mechanisms including
inhibition of leukocyte-endothelial interactions and
oxygen free radical scavenging.2-5
Nitric oxide is a well-known autocrine and paracrine
cellular mediator and prime moderator of pulmonary
vascular physiologic condition. It is thought to be ben-
eficial when administered by inhalation or intravenous
routes (through nitric oxide–donating agents) to either
donor or recipient. In addition to its involvement in vas-
cular homeostasis, nitric oxide is also a naturally occur-
ring inhibitor of neutrophil to endothelial adhesion.6,7
InSP6 is a phytic acid derivative that acts as a scav-
D espite advances in lung preservation technology,early graft dysfunction remains a significant prob-
lem. Lung ischemia-reperfusion injury is complex and
multifactorial but principally involves the sequestration
of activated neutrophils within the lung on reperfusion
with subsequent release of injurious granular enzymes
and oxygen free radicals.1
Several interventions have been suggested to modu-
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enger of oxygen free radicals. There is much evidence
from rodent models that this agent may also influence
neutrophil-endothelial interactions by inhibiting L and
P selectin–mediated adhesion.8
We investigated the actions of these agents and were
uniquely able to directly compare their effects in a
porcine model of single lung transplantation with fol-
low-up for 12 hours. This enabled us to assess which
intervention might be superior for subsequent use in
clinical practice.
Methods
Twenty female Landrace pigs (mean weight, 45.4 kg) were
divided randomly into 4 groups (n = 5 in each group). A sim-
ilar number were size and weight matched and acted as donor
animals. All grafts were reperfused at a mean pulmonary
artery pressure of 20 mm Hg.
Group A was a control group with no intervention admin-
istered; group B was reperfused with intravenous inositol
hexakisphosphate (0.02mg/kg/h), and group C was reper-
fused with intravenous SIN-1 (0.02mg/kg/h). Group D was
reperfused with the addition of intravenous pentoxifylline (20
mg/kg loading dose, then 2mg/kg/h). All interventions were
administered to the recipient animal only and began 5 min-
utes before reperfusion of the graft.
All animals received humane care in compliance with the
“Principles of Laboratory Animal Care” formulated by the
National Society for Medical Research and the “Guide for the
Care and Use of Laboratory Animals” prepared by the
National Academy of Science and published by the National
Institutes of Health (NIH publication 85-23, revised 1985).
All conditions associated with the United Kingdom Animals
(Scientific Procedures) Act 1986 were also met.
Donor operation. Animals were anesthetized with initial
intramuscular premedication with diazemuls (2 mg/kg) and
ketamine (15 mg/kg). Subsequent anesthesia was induced
with propofol (20 mg/kg) and maintained with isoflurane and
intravenous alfentanil. Animals were intubated with an endo-
tracheal tube (outside diameter, 9.5 mm) and ventilated at a
tidal volume of 15 mL/kg at an inspired oxygen concentration
of 100%.
Heart-lung blocks were retrieved in a standard manner,9
and lungs were preserved by flush perfusion with 60 mL/kg
of modified Euro-Collins through the main pulmonary artery.
After the separation of the left lung from the block, a pul-
monary artery pressure monitoring line (Cavafix Certo 18G;
Braun, Melsungen, Germany) was inserted through a purse-
string suture into the distal left pulmonary artery. A pul-
monary venous sampling line (Flocare; Nutricia, Madrid,
Spain) was similarly placed through the left atrial cuff direct-
ed into a distal pulmonary vein, allowing for later sampling
of venous blood from the graft without mixing from the con-
tralateral native lung after transplantation and reperfusion.
Lungs were stored inflated at a temperature of 4°C for a mean
ischemic time of 18.4 hours.
Recipient operation. Recipient animals were premedicated
with intramuscular azaperone (8 mg/kg) and diazemuls (2
mg/kg). After induction of anesthesia with intravenous
propofol, animals were maintained on intravenous pentobar-
bitone (30 mg/kg/h) and alfentanil. Venous and arterial pres-
sure monitoring lines were inserted as in donor animals.
Two endotracheal tubes were inserted through a tra-
cheostomy. A 9.5-mm outside diameter tube was placed into
the trachea to ventilate both lungs initially and subsequently
the native lung alone. The second 6.5-mm tube was advanced
through the left bronchial anastomosis after its completion to
ventilate the graft lung independently. Each endotracheal
tube was connected to a separate ventilator to permit individ-
ual lung ventilation after the transplantation, with a tidal vol-
ume of 15 mL/kg at 12 breaths per minute for each lung.
A left thoracotomy was followed by left pneumonectomy.
Implantation of the donor lung proceeded in an established
fashion constructing anastomoses of the left atrium, bron-
chus, and left pulmonary artery in order. The contralateral
pulmonary artery was encircled by a tape and snugger such
that the left pulmonary artery pressure could be manipulated.
A pressure monitoring line was placed in the recipient left
atrium, and a dedicated sampling line was inserted into the
proximal left pulmonary artery.
Pulmonary artery flow was measured with a 10-mm flow
probe (Transonic A-Series; Linton Instruments, Norfolk, UK)
placed around the left pulmonary artery distal to the anasto-
motic line. A similar 12-mm probe was placed around the
descending aorta to provide a guide to the cardiac output. Both
flow probes were connected to a dual channel HT207 medical
volume flowmeter (Transonic Systems Inc, Ithaca, NY)
All of the pressure and flow data sources were routed
through a CED 1401 32 channel digital to analogue converter
(Cambridge Electronic Design Ltd, Cambs, UK) and ac-
quired on a Gateway 2000 PC (Gateway 2000 Europe,
Clonshough, Dublin, Ireland) running Microsoft Windows 95
(Microsoft Ltd, Workingham, Berks, United Kingdom) and
Spike 2 (Version 4.0) data acquisition software (Cambridge
Electronic Design Ltd, Cambs, United Kingdom). Data were
collected continually over the 12-hour period after the opera-
tion and stored on a hard disk for subsequent analysis.
Pulmonary venous oxygen partial pressure (millimeters of
Mercury) was obtained from pulmonary venous sampling
line samples analyzed immediately on a blood gas analyzer
(Stat Profile 5, Nova Biomedical, Waltham, Mass).
Pulmonary vascular resistance (mm Hg/L/min) was calcu-
lated from the formula: (mean pulmonary artery pressure
[mm Hg]) – (left atrial pressure [mm Hg])/left pulmonary
artery flow (L/min).
Neutrophil trapping within the lung was calculated by
expressing the neutrophil count of blood exiting the lung,
measured from the sampling catheter in the graft pulmonary
vein, as a percentage of that entering the lung (measured from
the pulmonary artery sampling line) at each assessment inter-
val. Neutrophil sequestration was determined as a percentage
of the neutrophil count in pulmonary venous blood compared
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with the pulmonary arterial blood at a particular time point.
Thus values less than 100% indicate neutrophil trapping in
the lung, although values exceeding 100% indicate neutrophil
release from the lung.
Malonaldehyde, an important decomposition product of
lipid peroxides, is an indirect measure of free radical activity.
A spectrophotometric assay with an LPO-586 method
(Calbiochem-Novabiochem International, San Diego, Calif)
was used to quantify malonaldehyde in pulmonary venous
blood. Condensation of one molecule of malonaldehyde with
2 molecules of a proprietary chromogenic agent produces a
stable chromophore with maximal absorbance at 586 nm.
Five-milliliter samples of whole blood were collected in 48
m L of potassium EDTA 0.17 mmol/L. After centrifugation at
2500g for 10 minutes at 4°C, 200 m L of the supernatant was
collected in duplicate for use in the assay.
The sample was incubated for 40 minutes at 45°C with the
chromogenic substance then cooled on ice, and absorbance
was measured by spectrophotometer at 586 nm. The sensitiv-
ity of this method was determined as 0.5 m mol/L. In whole
blood samples of 200 m L, the lower limit of measurable mal-
onaldehyde was 2.5 m mol/L. Reproducibility was determined
by assays done over 10 days under identical experimental
conditions. With standard concentrations from 0 to 20
m mol/L, standard deviation was less than 5%.
Statistical methods. Although widely practiced, data ana-
lyzed using a 1-way analysis of variance to compare group
means at a series of time points (with the null hypothesis that
there is no difference between the group means at each point)
is flawed. Graphically, a line joining the mean values togeth-
er may not describe individual subjects within a study group
adequately so that a misleading impression is gained of the
trends in the data. No account is taken of the fact that mea-
surements at different time points are from the same subjects
with successive observations of an individual subject likely to
be correlated.10 To overcome these potential problems, statis-
tical examination using the individual, rather than the mean
of the group at each time point, as the basic unit for analysis
can be performed. A single number to summarize an individ-
ual subject’s response curve with time must be sought. This
reduces a large number of dependent observations to a small-
er number of summary measures.11 Time-related trends in
variables measured in reperfusion injury of the lung may be
either peaked or of growth type where the trend is increasing
or decreasing with time, such as the pulmonary venous oxy-
gen tension.
In our study, the summary measure of area under the curve
was used to describe the behavior of individual animals.
Groups of animals were then compared with the Scheffé
analysis of variance.
Results
Sequestration in the lung graft was observed in the
first 10 minutes after reperfusion in control group A,
with maximal sequestration occurring at 2 minutes.
Fig 1. Neutrophil sequestration after administration of pentoxifylline, SIN-1, and InSP6. Results are shown as the
mean value for animals in each intervention group (n = 5; group A, control; group B, inositol polyanions; group
C, SIN-1; group D, pentoxifylline). Error bars indicate the 95% confidence interval. Pre-reperfusion value is
shown at time 0. Note the significant attenuation of neutrophil sequestration in the intervention groups compared
with controls. Mean absolute value at time 0 = 6.4 · 109/L.
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After a plateau phase, lasting to 240 minutes after
reperfusion, neutrophils were released from the lung. In
groups B, C, and D, the administration of the pharma-
cologic agents abolished this biphasic pattern of
sequestration and subsequent release (Fig 1).
Analysis of variance showed that overall neutrophil
trapping in the graft was significantly reduced in
groups B, C, and D, compared with controls (P =
.026, P = .044, and P = .027, respectively). Pentox-
ifylline (group D) was as effective as SIN-1 (group C)
or InSP6 (group B) in this regard (P = .99). There was
no effect on platelet sequestration by any intervention
(Fig 2).
Malonaldehyde levels were significantly higher in
control lungs (group A) compared with groups B and D
(P = .02 and P = .001, respectively). Pentoxifylline
(group D) significantly lowered oxygen free radical
activity compared with groups A, B, and C (P = .0002,
P = .02, and P < .0001, respectively). In group C mal-
onaldehyde levels were significantly higher than in the
control group A (P = .001; Fig 3).
Pulmonary venous oxygen tension in the allograft
lung was worst in group A. Groups B and C indicated
that both inositol polyanions and SIN-1 conferred ben-
efit with superior oxygenation achieved (P = .0012 and
P = .0015, respectively), but they were similarly effec-
tive (P > .99). Group D was superior to all other groups
(P < .0001; Fig 4). The difference in partial pressure of
carbon dioxide between any treatment group and the
control group could be due to chance (P = .72).
Pulmonary vascular resistance was significantly
lower in all treatment groups compared with the control
group A. Both SIN-1 in group C (P = .02) and pentox-
ifylline in group D (P = .0011) reduced the pulmonary
vascular resistance compared with group B (Fig 5).
Repeated sampling did not significantly affect the
hematocrit of animals in any group over the time
course of the experiment.
Discussion
Our model of left single lung transplantation pro-
vides a stable and reproducible test bed, allowing fine
control of ventilation and perfusion of the lung graft,
while the animal is supported by the contralateral lung
irrespective of the function in the newly implanted
graft. The rigorous separation of the lungs in terms of
sample collection ensures that there is no mixing of
blood from the contralateral side.
Our data indicated that the initial 30 minutes after
reperfusion is the principle time of neutrophil seques-
tration in the lung and is the major initiator of reperfu-
sion injury.
The high pulmonary vascular resistance in this initial
period reflects the poor compliance of the pulmonary
Fig 2. Platelet sequestration after administration of pentoxifylline, SIN-1, and InSP6. Results are shown as the
mean value for animals in each intervention group (n = 5; group A, control; group B, inositol polyanions; group
C, SIN-1; group D, pentoxifylline). Error bars indicate the 95% confidence interval. Pre-reperfusion value is
shown at time 0. The interventions studied had no effect on platelet sequestration. Mean absolute value at time 0
= 265 · 109/L.
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vascular bed after cold ischemic storage and high
potassium levels. It may also be influenced by the high
levels of oxygen free radical release occurring during
this period of neutrophil trapping in the lung.
As the vascular bed dilates after this initial period of
reperfusion, pulmonary vascular resistance falls before
rising again as a consequence of the acute lung injury
resulting from reperfusion.
A period of neutrophil release was observed around
this time, and the analysis of area under the curve sug-
gests that the number of neutrophils released from the
lung exceeds the number trapped there in the first 30
minutes of reperfusion. We believe the explanation lies
with the pool of neutrophils remaining adherent to the
vascular endothelium of the lung during retrieval. The
role of these passenger leukocytes in the process of
reperfusion injury is unknown.
Of the interventions studied, inositol polyanions
(simple 6 carbon ring noncarbohydrate structures with
multiple ester-linked phosphate or sulphate groups)
appear to modulate reperfusion injury and may be of
therapeutic application.8
Sulphated or phosphorylated carbohydrates can inter-
act with L and P selectin and inhibit selectin-dependent
neutrophil-endothelial adhesion.12 These observations
suggest that multiple phosphate or sulphate groups may
act as ligands for at least 2 of the selectins and may
therefore be of use attenuating reperfusion injury.
The inhibitory effects of InSP6 on L and P selectin are
likely to be dependent on the number and structural posi-
tion of phosphate groups. Inositol itself has no effect on
neutrophil binding. The array of negative charge imparted
by the phosphate or sulphate groups may facilitate
binding to basic amino acids within the selectin molecule.
Cecconi and colleagues8 investigated a range of inos-
itol polyanions. In vitro, it was clearly demonstrated
that L and P selectin mediated binding to sLex was
inhibited although no inhibition of E selectin was
observed in these studies. Acute lung and peritoneal
inflammation experiments indicated that tissue neu-
trophil accumulation was significantly reduced (by
56% in the lung) in a dose-dependent manner in those
pretreated intravenously with InSP6. Interestingly,
peripheral blood neutrophil count was unaffected by
InSP6 administration. Of the small molecules tested,
InSP6 was deemed to be the most effective and was
therefore chosen for our series of experiments on lung
reperfusion injury.
Fig 3. Malonaldehyde levels after reperfusion with pharmacologic interventions. Results are shown as the mean
value for animals in each intervention group (n = 5; group A, control; group B, inositol polyanions; group C, SIN-
1; group D, pentoxifylline). Error bars indicate the 95% confidence interval. Pre-reperfusion value is shown at
time 0. Note that malonaldehyde levels are significantly attenuated by pentoxifylline and InSP6. SIN-1 adminis-
tration significantly elevated free radical levels compared with controls.
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Rao and colleagues13 investigated the antioxidant
role of myoinositol hexaphosphate (phytic acid) in a
rodent model of myocardial reperfusion injury. With a
Langendorff isolated heart system and a 30-minute
ischemic time, treated organs showed reduced creatine
kinase release and improved left ventricular function
concomitant with reduced lipid peroxidation assessed
by tissue malonaldehyde analysis. In contrast, Eggleton
and colleagues14 noted that, although preincubation
treatment of human neutrophils with InSP6 has no
effect on the basal unstimulated respiratory burst, the
response to a subsequent stimulus was substantially
enhanced. A substantial range of priming effect was
seen, but nevertheless this work suggests a priming
function in human neutrophils that may be detrimental
in reperfusion injury. However, these effects may
require pre-exposure to calcium and/or magnesium for
the priming action to be observed in vitro. Our findings
of attenuated reperfusion injury in the context of lung
transplantation suggests that this class of drug warrants
further investigation.
Nitric oxide also has beneficial effects on the patho-
physiologic features of reperfusion injury and was
superior to InSP6 in our study. The mechanisms by
which nitric oxide donors prevent leukocyte adhesion
are probably multifactorial. Inactivation of superoxide
inhibition of NADPH oxidase prevention of neutrophil
activation and effects on adhesion molecule expression
may all be important. Indeed, studies using the nitric
oxide synthase inhibitors L-NAME and L-NMMA to
influence leukocyte adhesion to exteriorized rat mesen-
teric postcapillary venules suggested that adhesion
increased 4-fold after nitric oxide inhibition within the
first 60 minutes.15
Nitric oxide also appears to have effects on the
CD11/CD18 system of adhesion molecules and
reduces constitutive expression of ICAM-1 on endothe-
lium.16 Nitric oxide, as a vasodilator, may also act
through a physical mechanism by increasing pul-
monary blood flow, raising shear stresses, and conse-
quently reducing the quantity of rolling neutrophils on
the pulmonary vascular endothelium.
The properties of nitric oxide with regard to endothe-
lial protection from neutrophil adhesion and free radi-
cal generation and in attenuating platelet aggregation
make nitric oxide of potential use in countering the
effects of reperfusion injury.17
Some work has been performed on inhaled nitric
oxide in this context, and significant pulmonary vasodi-
lation may be achieved without systemic hypotension in
concentrations of 5 to 80 ppm.18 Inhaled nitric oxide
may even be of benefit when administered to the donor
before organ procurement. The use of intravenously
administered nitric oxide donors (typified by glyceryl
Fig 4. Pulmonary venous PO2 (millimeters of mercury) with time after administration of pharmacologic inter-
ventions. Results are shown as the mean value for animals in each intervention group (n = 5; group A, control;
group B, inositol polyanions; group C, SIN-1; group D, pentoxifylline). Error bars indicate the 95% confidence
interval. Note superior function obtained with pentoxifylline treated lungs.
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trinitrate, sodium nitroprusside, and SIN-1) is less well
documented in pulmonary reperfusion injury.19,20 A
rodent model of remote pulmonary reperfusion injury
after aortic occlusion has shown intravenous nitroprus-
side can attenuate injury although L-NAME augments
pulmonary dysfunction by what appears to be a leuko-
cyte-dependent mechanism as judged by tissue
myeloperoxidase levels.6
In lung transplantation some preliminary work has
been performed by Naka and colleagues21 in a rodent
model of orthotopic lung transplantation. With nitro-
glycerin added to the graft flush preservation fluid and
a 4-hour ischemic time, after reimplantation, pul-
monary hemodynamics and function were enhanced,
compared with control animals. Furthermore, neu-
trophil sequestration, as measured by myeloperoxidase
assay, suggested less accumulation in nitric oxide–
treated lungs compared with controls. These studies
were limited to only 30 minutes of reperfusion, and
meaningful interpretation of these results is difficult.
Further work by Pinsky and colleagues7 confirmed
that nitric oxide levels fell precipitously after reperfu-
sion as did cyclic guanosine monophosphate. However,
supplementation of the flush preservation fluid with
cyclic guanosine monophosphate analog lowered pul-
monary vascular resistance and improved graft oxy-
genation over a 30-minute period of reperfusion. Most
recently, 10 dogs underwent left lung allotransplanta-
tion by Yamashita and colleagues.19 Donor lungs were
flushed with modified Euro-Collins solution and stored
for 21 hours. In the study group, the donor lung
received nitroprusside in the flush solution, and recipi-
ent animals received a continuous infusion during the
assessment period. Superior gas exchange and hemo-
dynamics were noted in lungs receiving nitroprusside
with less myeloperoxidase activity.
King and colleagues20 have experimented with an
isolated rabbit lung model, using sodium nitroprusside
as a nitric oxide donor, infused into the pulmonary
artery. Significant improvements were observed in pul-
monary hemodynamics, lung compliance, and edema,
even at low dose, indicating that this may be a valuable
strategy to pursue. The limitations imposed by an iso-
lated small animal organ model and the route of infu-
sion means that more clinically relevant large animal
studies with intravenous routes of drug administration
are warranted. These studies clearly suggest a potential
role for nitric oxide supplementation in the attenuation
of reperfusion injury.
However, concerns regarding the potential detrimen-
Fig 5. Pulmonary vascular resistance after reperfusion with pharmacologic interventions. Results are shown as
the mean value for animals in each intervention group (n = 5; group A, control; group B, inositol polyanions;
group C, SIN-1; group D, pentoxifylline). Error bars indicate the 95% confidence interval. All interventions sig-
nificantly reduced the pulmonary vascular resistance compared with controls.
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tal effects of nitric oxide administration have been
voiced. Specifically, endogenous superoxide may com-
bine with nitric oxide to produce the stable anion per-
oxynitrite and, subsequently, when protonated releases
hydroxyl radicals.
It may be that a precarious balance between the ben-
eficial effects of nitric oxide outlined earlier and the
generation of toxic products may exist and that it is
important to quantify these in detail if nitric oxide is to
be introduced as a potential prophylactic treatment for
reperfusion injury. Our study does not suggest that this
is a significant problem because, although malonalde-
hyde levels were significantly elevated, there were no
adverse effects on lung graft function.
For the purposes of this work, we selected SIN-1 as
the drug of choice because it is a more efficient nitric
oxide donor with few systemic effects. SIN-1 is the
active metabolite of the vasodilatory drug molsidomine
and is hydrolyzed to form SIN-1A, which undergoes
oxygen-dependent release of nitric oxide and superox-
ide. Rat studies on myocardial muscle have suggested
that this agent is more effective in preventing leukocyte
adhesion and transmigration compared with glyceryl
trinitrate and sodium nitroprusside and is more efficient
at preventing platelet aggregation. However, SIN-1 is
known to spontaneously decompose to release super-
oxide radicals and nitric oxide and to inhibit release of
plasminogen activator inhibitor from platelets.
The addition of pentoxifylline in the recipient confers
significant additional benefit over the other interven-
tions studied. Pentoxifylline has many functions, in
particular inhibiting the adherence of neutrophils to
endothelium and preventing leukocyte degranulation. It
may also inhibit the important interleukin-1, and tumor
necrosis factor, which are critical in the pathogenesis of
ischemia-reperfusion injury. Pentoxifylline clearly
improves and augments function by reducing neu-
trophil trapping in the lung and subsequent free radical
release. This agent has been beneficial in previous
porcine models of lung transplantation but never before
compared with other potential therapies. There has
been some suggestion that pentoxifylline is effective
when administered in flush solutions but not in recipi-
ent alone.22 Our findings seem to support the former,
although results are difficult to compare between dif-
ferent dose regimens and models.
These simple pharmacologic interventions can be
instituted easily in the operating theater in human
recipients. Our studies suggest that all the agents stud-
ied are free of systemic adverse effects.
Pentoxifylline (already licensed for use in humans in
peripheral vascular disease) is an inexpensive and safe
drug for use in lung transplant recipients and appears to
be superior to inositol polyanions and SIN-1 in terms
of graft function through attenuation of neutrophil
sequestration and free radical release. Adoption of
these interventions may lead to considerable improve-
ments in death and morbidity, shorter intensive care
stays, and costs among lung transplant recipients.
We thank Dr H.R. Matthews, Senior Lecturer in Medical
Statistics at the University of Newcastle upon Tyne, for his
advice regarding the statistical analysis of this data.
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